Recently Approved Drugs

Teflaro Teflaro (ceftaroline fosamil)
Cerexa Company: Cerexa
Approval Status Approved November 2010
Treatment Area Antibiotic; bacterial skin infections and bacterial pneumonia
General Information Teflaro (ceftaroline fosamil) is a novel fifth-generation cephalosporin, which exhibits broad-spectrum activity against Gram-positive bacteria, including MRSA and extensively-resistant strains.
Dificid Dificid (fidaxomicin)
Optimer Pharmaceuticals Company: Optimer Pharmaceuticals
Approval Status Approved May 2011
Treatment Area Antibiotic; Clostridium difficile-associated diarrhea
General Information Dificid (fidaxomicin) is a narrow-spectrum macrocyclic antibiotic, specifically indicated for Clostridium difficile-associated diarrhea in adults.
  Belviq (lorcaserin hydrochloride)
Arena Pharmaceuticals Company: Arena Pharmaceuticals
Approval Status Approved June 2012
Treatment Area Weight loss management
General Information Belviq (lorcaserin hydrochloride) is a serotonin 2C receptor agonist. It has been shown to decrease food consumption and promote satiety by selectively activating serotonin 2C receptors in the brain.
Stendra Stendra (avanafil)
Vivus Company: Vivus
Approval Status Approved April 2012
Treatment Area Erectile dysfunction
General Information Other similar drugs are sildenafil, tadalafil and vardenafil. The advantage of avanafil is that it has very fast onset of action compared with other PDE5 inhibitors.
Viibryd Viibryd (vilazodone hydrochloride)
Forest Laboratories Company: Forex Laboratories
Approval Status Approved January 2011
Treatment Area Major depressive disorder
General Information Viibryd (vilazodone hydrochloride) is a serotonergic antidepressant (a selective serotonin reuptake inhibitor and a 5HT1A receptor partial agonist) developed for the treatment of major depressive disorder.
Vascepa Vascepa (icosapent ethyl)
Amarin Pharmaceuticals Company: Amarin Pharmaceuticals
Approval Status Approved July 2012
Treatment Area Cholesterol lowring drug; Hypertriglyceridemia
General Information Vascepa is indicated for the treatment of very high levels of triglycerides. It contains ultra-purified ethyl EPA, an omega-3 fatty acid. Vascepa is the second prescription fish oil formulation, following GlaxoSmithKline‘s Lovaza.
Livalo Livalo (pitavastatin)
Kowa Company: Kowa Company
Approval Status Approved August 2009
Treatment Area Cholesterol lowring drug; Primary hyperlipidemia and mixed dyslipidemia
General Information Livalo (pitavastatin) is a highly potent novel synthetic statin engineered in Japan.